Figures & data
Figure 1 Molecular structure of fisetin.
Figure 2 Cytotoxicity of fisetin in leukemic cells and normal human lymphocytes. HL60 cells (▪) and normal human lymphocytes (▴) were treated with different concentrations of fisetin for 24 h. In the absence of fisetin, the MTT reduction was considered as 100%. The experiment was performed in a 24-well plate. Results represent the means ± standard error of three experiments run in triplicate (P < 0.05).
Figure 3 Effect of fisetin on MAPKs phosphorylation in HL60 cells. Cells were treated with different concentrations of fisetin (10, 20, 30 and 50 μM). Soluble lysates were matched for protein content and analyzed by Western blot. One representative immunoblot of three independent experiments is presented.
Figure 4 Fisetin changes the expression of NFκB p65. After treatment of HL60 cells with different concentrations of fisetin for 24 h, equal amounts of protein (50 μg) of total lysates were subjected to immunoblot analysis with NFκB (p65) antibodies.
Figure 5 Effect of fisetin on protein phosphorylation levels. Cells were treated with fisetin (10, 20, 30 and 50 μM), and the tyrosine (A) and threonine (B) phosphorylations were evaluated by immunoblotting. One representative immunoblot of three independent experiments is presented.
Table I. Effects of fisetin on antioxidant enzymes activities of HL60 cells. Cells were treated with fisetin (100 μM) and enzyme activities were determined as described in Materials and methods.